Study To Test Whether PF-00547659 Is Safe And Improves Disease Symptoms In Patients With Crohn's Disease
Status:
Completed
Trial end date:
2015-10-09
Target enrollment:
Participant gender:
Summary
Adults with Crohn's disease that is clinically active despite conventional treatment will be
eligible for this study. Patients may receive one of three doses of PF-00547659 (experimental
drug) or placebo (inactive drug). Disease activity will be measured every two weeks.